CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 2079
- Registration Number
- NCT00861926
- Locations
- 🇮🇹
Pr Papi, Ferrara, Italy
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 20
- Registration Number
- NCT00782535
- Locations
- 🇺🇸
Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States
🇺🇸University Clinical Research DeLand, LLC, DeLand, Florida, United States
🇺🇸New Horizons Clinical Research Center, Cincinnati, Ohio, United States
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 47
- Registration Number
- NCT00777595
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 54
- Registration Number
- NCT00742248
- Locations
- 🇮🇹
"Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Genova, Italy
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 57
- Registration Number
- NCT00640484
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States
Dose Finding Study of CHF 4226 for Treating Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 278
- Registration Number
- NCT00605891
- Locations
- 🇨🇿
Ordinace pro nemoci dychaciho ustroji, Beroun, Czech Republic
🇺🇸University Clinical Research - DeLand, LLC, DeLand, Florida, United States
🇵🇱NZOZ Non-nocere, Gdansk, Poland
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 180
- Registration Number
- NCT00528723
- Locations
- 🇮🇹
Unità Operativa Complessa di Clinica fisiologica e Pneumologia - Dipartimento di Medicina Interna e Specialità Mediche (DI.MI.) - Ospedale S. Martino e Cliniche Universitarie Convenzionate, Genova, Italy
🇷🇺City Clinical Hospital № 61, Pulmonology Department, Moscow, Russian Federation
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study
- Conditions
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 208
- Registration Number
- NCT00501982
- Locations
- 🇵🇹
Maternidade Alfredo da Costa, Lisbon, Portugal
🇪🇸Hospital De Cruces, Bilbao, Spain
🇨🇿General Faculty Hospital, Prague, Czechia
Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms
- Conditions
- Interventions
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 283
- Registration Number
- NCT00497523
- Locations
- 🇵🇱
Zaklad Alergologii Dzieciecej, Bialystok, Poland
🇵🇱Wojskovy Szpital Klinikzny, Krakow, Poland
🇵🇱Priwtny Gabinet Pediatriczno - Alergologiczny, Rabka Zdroj, Poland
Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma
- Conditions
- Interventions
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 382
- Registration Number
- NCT00497237
- Locations
- 🇮🇹
Ospedale Cardarelli - Fisiopatologia Respiratoria, Napoli, Italy
🇺🇦Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases of the Institute of Phthisiology and Pulmonology Academy of Medical Science of the Ukraine, Kiev, Ukraine
🇮🇹CNR - Dipartimento di Fisiopatologia Respiratoria, Palermo, Italy